Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 3:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 77 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-Daily Stereotactic Body Radiotherapy Clear all
Recruiting Phase 2 Interventional

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

NCT04302025
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Alectinib, Entrectinib, Vemurafenib, Cobimetinib, Pralsetinib, Atezolizumab, SBRT, Resection, Chemotherapy, Divarasib
Drug · Procedure
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
38
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Recruiting Phase 2 Interventional

BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

NCT04933903
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ipilimumab, Nivolumab, SBRT
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer

NCT02444741
View directory record Official record
Conditions
Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Pembrolizumab, Proton Beam Radiation Therapy, Radiation Therapy, Stereotactic Body Radiation Therapy
Radiation · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Terminated Phase 2 Interventional Results available

Chemoradiation +Gemcitabine +Continuous 5-FU (Fluorouracil) Followed by High Dose Brachytherapy/Stereotactic Radiation Boost in Locally Advanced Intra/Extrahepatic Cholangiocarcinoma

NCT00983541
View directory record Official record
Conditions
Cancer
Interventions
Fluorouracil (5-FU), Brachytherapy or SBRT (Stereotactic body radiation therapy), Gemcitabine
Drug · Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 1, 2026, 3:37 PM EDT
Withdrawn Not applicable Interventional

MRI Adaptive Replanning Using ViewRay

NCT02950792
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ViewRay MRI, Stereotactic Body Radiation Therapy Boost
Device · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 25, 2017 · Synced Oct 1, 2026, 3:37 PM EDT
Terminated Not applicable Interventional

Daily vs. Non-Daily SBRT for NSCLC

NCT03624907
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Daily Stereotactic Body Radiotherapy, Non-Daily Stereotactic Body Radiotherapy
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 4, 2021 · Synced Oct 1, 2026, 3:37 PM EDT
Active, not recruiting Phase 2 Interventional

Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma

NCT04331041
View directory record Official record
Conditions
Pancreas Cancer, Cancer of the Pancreas, Pancreas Adenocarcinoma
Interventions
Adaptive stereotactic body radiation therapy, Defactinib, Tumor biopsy, Research blood draw
Device · Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)

NCT03050554
View directory record Official record
Conditions
Early Stage Non-Small Cell Lung Cancer
Interventions
Avelumab, SBRT
Drug · Radiation
Lead sponsor
Andrew Sharabi
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
La Jolla, California • Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 1, 2026, 3:37 PM EDT
Active, not recruiting Phase 3 Interventional

Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer

NCT04214262
View directory record Official record
Conditions
Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8
Interventions
Atezolizumab, Biospecimen Collection, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Drug · Procedure · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
391
States / cities
Anchorage, Alaska • Jonesboro, Arkansas • Little Rock, Arkansas + 291 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Suspended Phase 1 Interventional

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

NCT05403723
View directory record Official record
Conditions
Extensive-stage Small-cell Lung Cancer
Interventions
Durvalumab 50 MG/1 ML Intravenous Solution, Etoposide Injection, Cisplatin, Carboplatin, Stereotactic Body Radiotherapy
Drug · Device
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer

NCT01899989
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Stereotactic Body Radiation Therapy (SBRT), cisplatin or carboplatin-based
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 1, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Study of SBRT/Olaparib Followed by Pembrolizumab/Olaparib in Gastric Cancers

NCT05379972
View directory record Official record
Conditions
Gastric Cancer, GastroEsophageal Cancer
Interventions
Pembrolizumab, Olaparib, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Colorado Spring, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

NCT07594522
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Photon or Proton standard stereotactic body radiotherapy (SBRT), Ivonescimab
Radiation · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Ovarian Cancer

NCT02582931
View directory record Official record
Conditions
Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
Interventions
MRI-guided SBRT, EORTC QLQ-C30 Questionnaire, EORTC QLQ-OV28 Questionnaire
Device · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 17, 2019 · Synced Oct 1, 2026, 3:37 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer

NCT04997018
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation Therapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Completed Phase 2 Interventional Results available

Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00547105
View directory record Official record
Conditions
Lung Cancer
Interventions
Erlotinib, SBRT
Drug · Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
2
States / cities
Aurora, Colorado • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2020 · Synced Oct 1, 2026, 3:37 PM EDT
Completed Not applicable Interventional Results available

Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy

NCT02357992
View directory record Official record
Conditions
Lung Cancer
Interventions
Stereotactic Body Radiotherapy (SABR)
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2022 · Synced Oct 1, 2026, 3:37 PM EDT
Recruiting Phase 2 Interventional

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

NCT05068232
View directory record Official record
Conditions
Small-cell Lung Cancer, Extensive-stage Small-cell Lung Cancer, Lung Cancer
Interventions
Ablative Radiation, Durvalumab, Etoposide, Carboplatin
Radiation · Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Recruiting Phase 2 Interventional

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma

NCT05384496
View directory record Official record
Conditions
Mucosal Melanoma
Interventions
Nivolumab and/or Ipilimumab, Stereotactic Body Radiation Therapy (SBRT), axitinib
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Active, not recruiting Phase 2 Interventional Results available

An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer

NCT05500092
View directory record Official record
Conditions
Resectable Stage IIA to IIIB Non-small Cell Lung Cancer
Interventions
Nivolumab, (8gy x 3), Platinum Doublet
Drug · Radiation
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
4
States / cities
St Louis, Missouri • The Bronx, New York • White Plains, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Completed Phase 1 Interventional

Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors

NCT00837928
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
bendamustine, laboratory biomarker analysis, Surgical Resection of Brain Metastases, Stereotactic body radiation therapy
Drug · Other · Procedure + 1 more
Lead sponsor
John Grecula
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 1, 2026, 3:37 PM EDT
Completed Phase 2 Interventional

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

NCT03589547
View directory record Official record
Conditions
Stage III Non-small-cell Lung Cancer
Interventions
Durvalumab, SBRT
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 1, 2026, 3:37 PM EDT
Recruiting Phase 3 Interventional

Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment

NCT07293585
View directory record Official record
Conditions
Prostate Cancer
Interventions
Neurovascular sparing stereotactic body radiation therapy
Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2036
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 1, 2026, 3:37 PM EDT
Not listed Phase 1 Interventional

An Alternative Radiation Fractionation Strategy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT01711697
View directory record Official record
Conditions
Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
Interventions
stereotactic body radiation therapy, carboplatin, paclitaxel, radiation therapy
Radiation · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
4
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 1, 2026, 3:37 PM EDT